期刊
TRENDS IN CARDIOVASCULAR MEDICINE
卷 17, 期 7, 页码 215-221出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2007.07.001
关键词
-
资金
- NHLBI NIH HHS [HL081741, R01 HL081741, R01 HL081741-03, P01 HL066941, P01 HL066941-07, 5P01HL066941] Funding Source: Medline
Congestive heart failure (CHF) affects more than five million people in the United States and results in considerable morbidity, mortality, and economic costs. Patients with class III and IV CHF have a 40% to 50% probability of dying 5 years after symptom onset despite optimal therapy, a prognosis worse than many cancers. A variety of drugs and devices have improved survival-the 50% survival time in 1980 was just 18 months-but the outlook for patients remains disinal and the prevalence of CHF continues to increase. This unmet medical need underscores the importance of developing new approaches for the treatment of CHF This brief review focuses on data from preclinical experiments regarding the effects of increased adenylyl cyclase type 6 (AC6) expression on cellular and cardiac function, and possible mechanisms for the unexpected favorable effects of increased AC6 content on the failing heart. (Trends Cardiovasc Med 2007; 17:215-22 1) (c) 2007, Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据